Image
Recommendation
Anti-HER2 therapy – Indications #2
Consider trastuzumab in addition to chemotherapy as adjuvant treatment for patients with T1a/T1b HER2-positive breast cancer, taking into account any comorbidities, prognostic features and possible toxicity of chemotherapy.
Consider trastuzumab as adjuvant treatment for people with T1a/T1b HER2-positive invasive breast cancer, taking into account any comorbidities, prognostic features and possible toxicity of chemotherapy
How this guidance was developed
This recommendation was adopted from the NICE 2018 guidelines (UK). The source recommendation was based on a systematic review of the evidence conducted to September 2017 and used wording (‘Consider’) indicative of a conditional recommendation (using GRADE methods) by the source guideline authors as the evidence shows that only a small number of people with breast cancer will benefit from this treatment. The source recommendation was accepted with no changes.
Anti-HER2 therapy – Indications #2
Recommendation
Consider trastuzumab in addition to chemotherapy as adjuvant treatment for patients with T1a/T1b HER2-positive breast cancer, taking into account any comorbidities, prognostic features and possible toxicity of chemotherapy.
Principles in action
Patient-centred care
This recommendation was adopted from the NICE 2018 guidelines (UK). The source recommendation was based on a systematic review of the evidence conducted to September 2017 and used wording (‘Consider’) indicative of a conditional recommendation (using GRADE methods) by the source guideline authors as the evidence shows that only a small number of people with breast cancer will benefit from this treatment. The source recommendation was accepted with no changes.